ReST Therapeutics is a preclinical Biotech leveraging its successful Seed Funding to advance our proprietary drug candidate through non-clinical testing and achieve the First in Human clinical study.

Latest News

USPTO grants ReST Therapeutic’s Patent on PTSD

On October 11, 2022, the USPTO issued ReST Therapeutics a patent on the use of its drug candidate FENM for the treatment of anxiety and PTSD. ReST Therapeutics'  project is to develop a proprietary drug candidate for the treatment of  Post-Traumatic Syndrome and...

FENM facilitates extinction learning without sensorimotor deficits

International Journal of Neuropsychopharmacology, 2021 Jul 14;24(6):519-531. https://doi.org/10.1093/ijnp/pyab007 Fluoroethylnormemantine, A Novel Derivative of Memantine, Facilitates Extinction Learning WithoutSensorimotor Deficits. Briana K. Chen, Gwenaëlle Le Pen,...